Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: An analysis of the Food and Drug Administration database

Objective. The assumption that psychotic patients assigned to placebo in cl inical trials of antipsychotics are exposed to substantial morbidity and mo rtality is not based on data about what actually happens to such patients. This study assesses symptoms and risks of suicide and suicide attempts in p sychotic patients assigned to receive placebo in clinical trials. Method: The authors used the Food and Drug Administration database to asses s suicides, suicide attempts, and psychotic symptom reduction in clinical t rials of three new antipsychotics. Results, Among 10,118 participating patients, 26 committed suicide and 51 a ttempted suicide. Rates of suicide and attempted suicide did not differ sig nificantly between the placebo-treated and the drug-treated groups. Annual rates of suicide and attempted suicide based on patient exposure years were 1.8% and 3.3%, respectively, with placebo; 0.9% and 5.7% with an establish ed antipsychotic; and 0.7% and 5.0% with a new antipsychotic. Symptom reduc tion was 16.6% with new antipsychotics (N=1,203), 17.3% with established an tipsychotics (N=261), and 1.1 % with placebo (N=462). Conclusions: These data may help inform discussions about the use of placeb o in antipsychotic clinical trials.